Q1 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
CosentyxⓇ ex-US growth offset by US decline. Global FY sales
expected broadly in line with PY
GROWTH
Sales evolution
USD m, % cc
Ex-US
US
1,159
500
-4%
1,076
548
659
528
Q1 2022
Q1 2023
Q1 performance
US: Demand growth offset by revenue deductions (incl. PY base impact)
Ex-US: Strong growth in core indications
China: Outperforming market with double-digit growth post-COVID
2023: Expect FY sales broadly in line with PY
(H1 decline and H2 growth)
Future growth mainly driven by life cycle management
EU: CHMP opinion for HS expected Q2
US: HS/ IV approvals expected H2
Lupus Nephritis and Giant Cell Arthritis Phase 3 trials on track
New Phase 3 trials initiated in Polymyalgia Rheumatica and
Rotator Cuff Tendinopathy
CHMP Committee for Human Medicinal Products. HS-hidradenitis suppurativa. IV - intravenous.
13 Investor Relations | Q1 2023 Results
Cosentyx®
NOVARTIS | Reimagining MedicineView entire presentation